2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
MP Wattjes, O Ciccarelli, DS Reich, B Banwell… - The Lancet …, 2021 - thelancet.com
Summary The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned
EO Major, TA Yousry, DB Clifford - The Lancet Neurology, 2018 - thelancet.com
Progressive multifocal leukoencephalopathy (PML) is a rare, devastating demyelinating
disease of the CNS caused by the JC virus (JCV) that occurs in patients with compromised …
disease of the CNS caused by the JC virus (JCV) that occurs in patients with compromised …
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater …
A Svenningsson, T Frisell, J Burman, J Salzer… - The Lancet …, 2022 - thelancet.com
Background B-cell depleting therapies are highly efficacious in relapsing-remitting multiple
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …
Chronic inflammation in multiple sclerosis—seeing what was always there
PM Matthews - Nature Reviews Neurology, 2019 - nature.com
Activation of innate immune cells and other compartmentalized inflammatory cells in the
brains and spinal cords of people with relapsing–remitting multiple sclerosis (MS) and …
brains and spinal cords of people with relapsing–remitting multiple sclerosis (MS) and …
[HTML][HTML] Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis
Objectives To compare the cross-sectional robustness of commonly used volumetric
software and effects of lesion filling in multiple sclerosis (MS). Methods Nine MS patients (six …
software and effects of lesion filling in multiple sclerosis (MS). Methods Nine MS patients (six …
Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis
C Starvaggi Cucuzza, E Longinetti… - Neurology …, 2022 - AAN Enterprises
Background and Objectives B cell–depleting therapies are highly effective in relapsing-
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …
New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions
Purpose New multiple sclerosis (MS) disease-modifying therapies (DMTs), which exert
beneficial effects through prevention of relapse, limitation of disability progression, and …
beneficial effects through prevention of relapse, limitation of disability progression, and …
Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: a real‐world investigation
I Rosenstein, S Rasch, M Axelsson… - Journal of …, 2021 - Wiley Online Library
Kappa free light chain (KFLC) index, a measure for intrathecal production of free kappa
chains, has been increasingly recognized for its diagnostic potential in multiple sclerosis …
chains, has been increasingly recognized for its diagnostic potential in multiple sclerosis …
[HTML][HTML] A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
S Sandgren, L Novakova, A Nordin, M Axelsson… - Frontiers in …, 2023 - frontiersin.org
Background Alemtuzumab (ALZ) is a pulsed immune reconstitution therapy for multiple
sclerosis (MS). Objective To assess basic characteristics, therapeutic effects, and prognostic …
sclerosis (MS). Objective To assess basic characteristics, therapeutic effects, and prognostic …
[HTML][HTML] High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
I Rosenstein, M Axelsson, L Novakova… - Frontiers in …, 2023 - frontiersin.org
Background Evolving evidence suggests that measurement of cerebrospinal fluid (CSF)
kappa free light chain (KFLC) synthesis has high diagnostic sensitivity and specificity for …
kappa free light chain (KFLC) synthesis has high diagnostic sensitivity and specificity for …